Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OS-01 is a proprietary synthetic decapeptide (Decapeptide-52) developed by OneSkin and used as the active ingredient in their topical skin longevity products. It is scientifically characterized as a "senomorphic" or "senotherapeutic" peptide that targets cellular senescence—a key driver of skin aging—by reducing the burden of senescent cells and promoting healthier cell renewal. The mechanism involves modulating pathways associated with cellular aging to improve skin health at the molecular level. Clinical studies have shown that topical application of products containing the OS-01 peptide can reduce biological age markers in human skin models and improve visible signs of aging such as fine lines and loss of elasticity[3][6][7]. The peptide is formulated into various over-the-counter cosmetic creams marketed for daily use to support youthful skin appearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OS-01 peptide.